洛杉矶加利福尼亚大学的Antoni Ribas及其同事在会议上报告称,135名接受Lambrolizumab治疗的黑色素瘤病人中,有超过三分之一的肿瘤缩小了。
Some of these people had previously been treated, unsuccessfully, with ipilimumab,confirming that the two drugs really do work in different ways.
有些人之前接受ipilimumab治疗却没有成效,证明了这两种药物确实有着不同的工作机制。
Those separate modes of action were also confirmed by work announced to the meetingby Jedd Wolchok of the Memorial Sloan-Kettering Cancer Centre, in New York.
两种制剂相互独立的作用机制也由Jedd Wolchok向大会所做的工作汇报证明。
He and his colleagues reported that a combination of ipilimumab and nivolumab causesfaster and more complete responses than either does on its own. So far, they have treated 52people.
Jedd来自纽约斯隆凯特林癌病中心,他和同事们称ipilimumab和nivolumab结合使用比单独使用产生更快更彻底的效果。
The tumours of around three-quarters of these patients began shrinking in the first 12 weeksof treatment.
目前他们治疗了52位病人,约有四分之三的的肿瘤在治疗初的12周内开始缩小,
In a third of cases tumours shrank by 80% or more in that period and in 90% the patient wascontinuing to respond at his last check-up.
【2015考研英语阅读癌症治疗】相关文章:
最新
2016-10-18
2016-10-11
2016-10-11
2016-10-08
2016-09-30
2016-09-30